Third, ACVR1 inhibition or deletion abolished the anti‐lymphoma effect of PRC2 inhibitors in cell culture and xenograft tumors, likely through blocking differentiation and immunological synapse‐mediated signaling in lymphoma. Here, ACVR1 is linked to lymphoma.